Clinical Trial

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Study acronym: PIPOZA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-02; most recent amendment 2025-08-04.
Status change: Not Yet Recruiting → Recruiting 2025-05-09
Trial Details
NCT Number NCT06812715
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Eli Lilly and Company
Conditions Chronic Lymphocytic Leukemia
Enrollment 40 participants
Start Date 2025-05-05
Primary Completion 2029-05 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2025-08-06